Prothena grants 190,000 stock options to CSO

Zago Wagner M. reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 03/05/2026 - 04:51 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Zago Wagner M. reported acquisition or exercise transactions in this Form 4 filing.

PROTHENA CORP PUBLIC LTD CO reported that Chief Scientific Officer Zago Wagner M. was granted a stock option covering 190,000 shares of the company’s stock. The option was reported at a grant price of $0.00 per share and is held as direct ownership.

According to the vesting terms, 25% of the total shares under the option will vest and become exercisable on March 3, 2027. The remaining shares will vest in 1/48th increments in equal monthly installments on each monthly anniversary after that date, conditioned on Wagner’s continued employment with the company on each vesting date.

Insider Trade Summary

Grant/Award: 190,000 shares

Grant/Award 1 txn

Insider Zago Wagner M.

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	190,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 190,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 3, 2027, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PROTHENA (PRTA) report for Zago Wagner M.?

PROTHENA reported a grant of stock options to Chief Scientific Officer Zago Wagner M. covering 190,000 shares. The Form 4 describes this as a grant or award acquisition, increasing his directly held derivative position in the company’s stock through a new option award.

How many PROTHENA (PRTA) shares are covered by the new stock option grant?

The new stock option grant covers 190,000 shares of PROTHENA common stock. This entire amount is reflected as derivative securities, with 190,000 shares shown as held following the transaction, indicating the full award size reported in this Form 4 filing.

What are the vesting terms for the 190,000 PROTHENA (PRTA) stock options?

The option vests 25% of the total shares on March 3, 2027, then 1/48th of the total shares in equal monthly installments thereafter. Each vesting installment is conditioned on the reporting person’s continued employment with PROTHENA on the applicable vesting date.

What is the transaction code and direction for this PROTHENA (PRTA) insider award?

The transaction uses code A, described as a grant, award, or other acquisition. It is classified as an acquisition of derivative securities, not an open-market purchase, and is reported as a direct ownership position by the Chief Scientific Officer in this Form 4.

When will the PROTHENA (PRTA) stock option first become exercisable for the insider?

The stock option will first become exercisable for 25% of the total 190,000 shares on March 3, 2027. Additional shares will then become exercisable in equal monthly installments, contingent on the insider’s continued employment with PROTHENA on each respective vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zago Wagner M.

(Last) (First) (Middle)

C/O PROTHENA BIOSCIENCES INC

1800 SIERRA POINT PARKWAY

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PROTHENA CORP PUBLIC LTD CO [ PRTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.36	03/03/2026		A		190,000		(1)	03/03/2036	Ordinary Shares	190,000	$0	190,000	D

Explanation of Responses:

1. The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 3, 2027, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.

	/s/ Michael J. Malecek, as Attorney-in-Fact for Wagner M. Zago	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.